English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia

Schroeter, M. L., Abdul-Khaliq, H., Frühauf, S., Höhne, R., Schick, G., Diefenbacher, A., et al. (2003). Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophrenia Research, 62(3), 231-236. doi:10.1016/S0920-9964(02)00383-3.

Item is

Files

show Files
hide Files
:
Schroeter_Serum.pdf (Publisher version), 112KB
Name:
Schroeter_Serum.pdf
Description:
-
OA-Status:
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Schroeter, Matthias L.1, Author           
Abdul-Khaliq, H., Author
Frühauf, S., Author
Höhne, R., Author
Schick, G., Author
Diefenbacher, A., Author
Blasig, I. E., Author
Affiliations:
1MPI of Cognitive Neuroscience (Leipzig, -2003), The Prior Institutes, MPI for Human Cognitive and Brain Sciences, Max Planck Society, ou_634574              

Content

show
hide
Free keywords: Antipsychotics; Astrocytes; Deficit syndrome; S100B protein; Schizophrenia; Thought disturbance
 Abstract: Previous studies reported controversial results concerning alterations of astrocytes in schizophrenia. Because S100B may be regarded as a marker for astrocytes, the objective of this study was to examine S100B serum concentrations in 30 patients with schizophrenia with a monoclonal two-site immunoluminometric assay that specifically detects S100B. An ANOVA revealed medication (p<0.005) and deficit vs. nondeficit syndrome (p<0.05) as factors that influenced S100B significantly. S100B was higher in schizophrenic patients treated with antipsychotic drugs for approximately 3 weeks (241.1±152.5 ng/l) in comparison with unmedicated patients (111.4±31.8 ng/l, p<0.005), and healthy age-matched controls (112.8±53.4 ng/l, p<0.001; Bonferroni corrected two-tailed Student's t-test). There was no difference of S100B between unmedicated patients and controls (p>0.05). Patients with deficit (250.6±154.9 ng/l) had higher S100B levels than patients with nondeficit schizophrenia (146.7±107.2 ng/l, p<0.05) or controls (p<0.005). S100B was positively correlated with the subscore ‘thought disturbance’ of the Brief Psychiatric Rating Scale (p<0.05). In summary, increased serum levels of S100B may indicate alterations of astrocytes during early treatment with antipsychotics and in deficit schizophrenia. Whether S100B is elevated due to injured astrocytes and a disrupted blood–brain barrier, or by active secretion of S100B by astrocytes, has to be clarified by further studies.

Details

show
hide
Language(s): eng - English
 Dates: 2003
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: eDoc: 239715
Other: P7083
DOI: 10.1016/S0920-9964(02)00383-3
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Schizophrenia Research
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Amsterdam : Elsevier
Pages: - Volume / Issue: 62 (3) Sequence Number: - Start / End Page: 231 - 236 Identifier: ISSN: 0920-9964
CoNE: https://pure.mpg.de/cone/journals/resource/954925564675